Anti-inflammatory potential of myricetin in leukemia cells: in silico and in vitro exploration

A conventional plant flavonoid known as myricetin is well-known for its wide range of effects, including its strong anti-inflammatory, anti-cancer, and antioxidant characteristics. In this study, we examined anti-inflammatory potential of Myricetin (MN) by looking at the expressions of COX-2, IL-6 and TNF-α in leukemia cancer cell lines (THP-1). The THP-1 was cultured in Roswell Park Memorial Institute medium supplemented with 10% foetal bovine serum and penicillin (100 U/ml) for the purposes of the in-vitro investigations. Cell viability and cytotoxicity testing were done using the MTT assay. To prepare the ligand and proteins for the in-silico studies, The structures of the targeted anti-inflammatory proteins COX-2 (PDB ID: 5KIR), TNF- (PDB ID: 1TNF), and IL-6 (PDB ID: 1ALU) were retrieved from Protein Data Bank. Furthermore, docking experiments were carried out using the AutoDock Vina software. In comparison to the reference drug cisplatin (9.46 µg/ml) the IC50 value for MN was found to be 90.161 µg/ml. The cells pretreated with MN showed a significantly lower expression of anti-inflammatory components (COX-2, TNF-α and IL6) upon measured by geometric mean fluorescence intensity as compared to the LPS-induced control cells. Additionally, MN has shown a strong interaction with COX-2, TNF-α and IL-6 in simulation studies. To conclude, MN exhibits a potent anti-inflammatory effect both in-silico and in-vitro studies. Further, in vivo investigations are needed to gain more comprehensive understanding of the molecule.